Ginsenosides are novel naturally-occurring aryl hydrocarbon receptor ligands.

Permalink
https://escholarship.org/uc/item/85g2j015

Journal
PloS one, 8(6)

ISSN
1932-6203

Authors
Hu, Qin
He, Guochun
Zhao, Jing
et al.

Publication Date
2013

DOI
10.1371/journal.pone.0066258

Peer reviewed
Ginsenosides Are Novel Naturally-Occurring Aryl Hydrocarbon Receptor Ligands

Qin Hu1, Guochun He2, Jing Zhao2, Anatoly Soshilov2, Michael S. Denison2, Aiqian Zhang1, Huijun Yin3, Domenico Fracalvieri4, Laura Bonati4, Qunhui Xie1, Bin Zhao1*

1 Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing, China, 2 Department of Environmental Toxicology, University of California, Davis, California, United States of America, 3 Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China, 4 Department of Earth and Environmental Sciences, University of Milano-Bicocca, Milan, Italy

Abstract

The aryl hydrocarbon receptor (AHR) is a ligand-dependent transcription factor that mediates many of the biological and toxicological actions of structurally diverse chemicals. In this study, we examined the ability of a series of ginsenosides extracted from ginseng, a traditional Chinese medicine, to bind to and activate/inhibit the AHR and AHR signal transduction. Using a combination of ligand and DNA binding assays, molecular docking and reporter gene analysis, we demonstrated the ability of selected ginsenosides to directly bind to and activate the guinea pig cytosolic AHR, and to stimulate/inhibit AHR-dependent luciferase gene expression in a recombinant guinea pig cell line. Comparative studies revealed significant species differences in the ability of ginsenosides to stimulate AHR-dependent gene expression in guinea pig, rat, mouse and human cell lines. Not only did selected ginsenosides preferentially activate the AHR from one species and not others, mouse cell line was also significantly less responsive to these chemicals than rat and guinea pig cell lines, but the endogenous gene CYP1A1 could still be induced in mouse cell line. Overall, the ability of these compounds to stimulate AHR signal transduction demonstrated that these ginsenosides are a new class of naturally occurring AHR agonists.

Introduction

The aryl hydrocarbon receptor (AHR) is a basic helix-loop-helix PAS-containing transcription factor, which activates gene expression in a ligand-dependent manner [1]. Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin), the prototypical and most potent AHR ligand, results in a wide variety of species- and tissue-specific toxic and biological responses, the majority of which are AHR dependent [2,3]. Following ligand binding, the cytosolic AHR protein complex, which contains two molecules of hsp90, the X-associated protein 2, and the co-chaperone p23, translocates into the nucleus [4,5], the ligand-bound AHR is released upon its dimerization with the ARNT (Ah receptor nuclear translocator) protein, and the AHR is converted into its high-affinity DNA binding form [1,6,7]. Binding of the heteromeric ligand:AHR:ARNT complex to its specific DNA recognition site, the dioxin response element (DRE), upstream of cytochrome P4501A1 (CYP1A1) and other AHR-responsive genes, stimulates their transcription [1,3].

The best characterized high-affinity ligands for the AHR include a variety of synthetic halogenated aromatic hydrocarbons (HAHs), such as the polychlorinated dibenzo-p-dioxin, dibenzofurans, and dibenzo-p-dioxins, and biphenyls, as well as numerous polycyclic aromatic hydrocarbons (PAHs), such as benzo[a]pyrene, 3-methylcholanthrene, and others [2,8]. More recently, a relatively large number of natural and synthetic AHR ligands (agonists and antagonists) whose structures and physicochemical characteristics are dramatically different from that of the prototypical HAH and PAH have been identified and characterized [9–11]. While the relative potencies of these diverse ligands in intact cells and animals are typically much lower than that of the HAHs and PAHs, predominantly due to differences in their affinity, intrinsic efficacy, and metabolic stability [8,10–12], these results demonstrate that the AHR has an extremely promiscuous ligand binding pocket, and raised questions as to the actual spectrum of chemicals that can bind to and activate the AHR and AHR signaling pathway. Accordingly, we have carried out bioassay screening analysis of a wide variety of natural compounds and extracts with the goal to identify and characterize novel AHR ligands, and extend our understanding of the AHR ligand structural diversity.

Ginseng has been used as traditional medicine in China, Korea, Japan and other Asian countries for thousands of years. While there are seven major species of ginseng in East Asia, Central Asia, and North America, most studies have focused on constituents from three common species: Panax ginseng (Asian ginseng), Panax quinquefolius (American ginseng), and Panax japonicus (Japanese ginseng). The majority of the diverse pharmacological and biochemical actions of ginseng appeared to be attributed to ginseng saponins (ginsenosides), and more than 60 different ginsenosides have been isolated from members of the Panax genus [13]. While there is was antagonistic action by the ginseng
saponin components resulting in inhibition of cellular proliferation, ginsenosides can also stimulate cell growth [14].

The diversity of AHR ligand structure coupled with the ability of numerous natural products to bind to the AHR [8–11], and the recent identification of two common clinically used ginsenosides (Rg1 and Rb1) that can increase CYP1A1 mRNA levels in human cells in culture [15], suggests that these compounds may be AHR ligands. However, while induction of human CYP1A1 gene expression is known to be mediated by the AHR, several studies have also demonstrated induction by the retinoic acid receptor and other signaling mechanisms [3,16–18]. Additionally, since the study of Wang et al. (2008) did not determine whether these compounds directly stimulated induction of CYP1A1, or whether the response was secondary (i.e. due to a ginsenoside metabolite or activation of an alternative pathway), the mechanism(s) responsible for ginsenoside-dependent induction of CYP1A1 still remains an open question [15]. Accordingly, here we described the results of studies examining the ability of a series of ginsenosides to stimulate AHR-dependent gene expression and confirmed their identity as AHR ligands.

Materials and Methods

Chemicals

The specific ginsenosides used in this study (Rb1, Rb2, Rb3, Rc, Rd, Rf, Rg1, Rg2, Rh1, Rh2, PPD, PPT, F11, and a total ginsenosides (TG) mixture (Figure 1 & Table 1), were kindly provided by Dr. Huijun Yin (Chinese Academy of Medical Sciences, Beijing, China) and were of greater than 98% purity. TCDD, 2,3,7,8-tetrachlorodibenzofuran (TCDF), and [3H]-TCDD (10 Ci/mmol) were obtained from S. Safe (Texas A&M University, College Station, TX USA). [32P]-ATP (6000 Ci/mmol) was purchased from Amersham (Arlington Heights, IL USA) and DMSO from Sigma-Aldrich. Cell culture media was provided by Gibco (Invitrogen), fetal calf serum was purchased from Lonza (BioWhittaker) and G418 was from Gemini Bio-Products (Woodland, CA USA). Water was purified using a Milli-Q water purification system (Millipore). All other chemicals were of analytic purity.

Cell Culture, Chemical Treatment, and Ahr-Dependent Luciferase Reporter Gene Expression

Recombinant guinea pig intestinal adenocarcinoma (G16L1.1c6) cells and rat (H4L1.1c4), mouse (H1L1.1c2) and human (HG2L6.1c3) hepatoma cells were grown and maintained as described [19]. G16L1.1c8, H4L1.1c4 and H1L1.1c2 cells contain the stably integrated DRE-driven firefly luciferase reporter plasmid pGudLuc1.1, HG2L6.1c3 cells contain pGudLuc6.1 [20] and the transcriptional activation of those plasmids occurs in a time-, ligand-, dose-, and AHR-dependent manner [19,21]. Cells were plated into white, clear-bottomed 96-well tissue culture dishes at 75,000 cells per well and allowed to attach for 24 h. Cells were incubated with carrier solvent DMSO (1% final solvent concentration), TCDD (1 nM), or the indicated ginsenoside (for measurement of agonist activity), or 1 nM TCDD plus the indicated ginsenoside (for measurement of antagonist activity) for 4 h at 37°C. For luciferase measurement, sample wells were washed twice with phosphate-buffered saline, followed by the addition of cell lysis buffer (Promega) and shaking of the plates for 20 min at room temperature to allow cell lysis. Measurement of luciferase activity in each well was carried out using a microplate luminometer (TECAN Infinite 200 Multi Reader) with automatic injection of Promega stabilized luciferase reagent. Luciferase activity in each well was expressed relative to that induced by 1 nM TCDD.

Homology Modeling

The LBD structure of the guinea pig AHR (gpAHR) was predicted by homology modeling, using the same procedure previously adopted for the mouse, rat and human AHRs (mAHR, rAHR, hAHR) [22]. In brief, three X-ray structures of HIF-2α co-crystallized with the THS ligands (3F1O, 3H7W and 3H82) were used as templates. MODELLER version 9v7 [23–25] was used to perform homology modeling, by activating the option to transfer all the THS structures from the templates to the final homology model. One hundred models were obtained by random generation of the starting structure and the DOPE score [26] was used to rank the models. Four conformational clusters were identified in this set of models, and a representative conformation for each cluster (the one with the best DOPE score) was selected for the ensemble docking calculations.

| Table 1. Structures of ginsenosides examined in this study. |
|---|
| Category | Name | Side chain |
|---|
| PPD type | Rb1 | -Glc2-Glc | -Glc6-Glc |
| Rb2 | -Glc2-Glc | -Glc6-Ara(p) |
| Rb3 | -Glc2-Glc | -Glc6-Xyl |
| Rc | -Glc2-Glc | -Glc6-Ara(f) |
| Rd | -Glc2-Glc | -Glc |
| Rh2 | -Glc | -H |
| PPD | -H | -H |
| PPT type | Re | -Glc2-Rha | -Glc |
| Rg1 | -Glc | -Glc |
| Rg2 | -Glc2-Rha | -H |
| Rh1 | -Glc | -H |
| PPT | -H | -H |
| Special type | F11 |
| TG |

Abbreviations for carbohydrates are as follow: Glc, glucopyranoside; Ara, arabinopyranoside; Rha, rhamnopyranoside; Xyl, xylopyranoside; TG, total ginsenosides (mixed compounds). Superscripts indicated the carbon in the glucose ring that linked the two carbohydrates. doi:10.1371/journal.pone.0066258.t001

Figure 1. Backbone structures of ginsenosides. Each type of ginsenosides differ at two side chains OR1 and OR2 attached to the common steroid ring.

doi:10.1371/journal.pone.0066258.g001
Ligand Conformational Analysis

Conformational search of the ginsenoside ligands (PPD and PPT) in the free state was performed using the MacroModel 9×9 [27] program included in Maestro 9×3 [28] with the following parameters: OPLS-2005 force field [29], implicit (Generalized Born/Solvent Accessible, GB/SA) water solvation [30], automatic set up of the conformational degrees of freedom, and Monte Carlo Multiple Minimum (MC/MM) random search algorithm. The five most stable conformational minima for each ligand were selected for docking calculations.

Molecular Docking

The ensemble docking approach previously proposed for ligand docking to the AHR homology models [22] was used. Accordingly, the four representative conformations selected in the ensemble of homology models of the gpAHR were used for docking. To account for the ginsenosides’ conformational variability, the five conformations selected for PPD and PPT were utilized for docking analysis. Flexible ligand docking of the two ginsenosides and the TCDD was carried out using the Glide 5.8 program [31] with the Glide extra-precision (XP) protocol [32]. The binding box was centered in the averaged Cartesian coordinates of the template THS ligands centroids, with 25 Å sides length. All the other parameters were of the default ones. The final best scoring pose for each ligand was selected by using the Glide XP scoring function [32]. Docking calculations with the same ligands were performed, for comparative purposes, in the modeled mAHR, nAHR and huAHR LBDs [22] using the same computational protocol.

Refinement of The Docking Poses

Energy minimization of all the obtained AHR/ligand complexes was carried out with the MacroModel 9.9 program [27,28]. The OPLS-2005 force field [29], the implicit GB/SA water solvation model [30] and the TNCG minimization algorithm were employed in this analysis. Different degrees of system flexibility were imposed: the ligands and the side chains of the residue shell within 5 Å from the ligands were defined as free to move; the backbone of the residue shell within 5 Å from the ligands were constrained with a force constant of 200 kJ/mol·Å²; the residues within 5–7 Å from the ligands were constrained with a force constant of 500 kJ/mol·Å⁴, and all the remaining residues were frozen.

Rt-Pcr Analysis of Endogenous Gene Cyp1a1 Induction

Forward and reverse RT-PCR primers were synthesized and contained the following sequences: mCYP1A1 FP, 5’-CCTCATTGACCTTGGTAAACCA-3’; and mCYP1A1 RP, 5’-AAGGATGAATGCCGGAAGGT-3’, and a highly conserved region of a constitutively expressed housekeeping gene, GAPDH FP, 5’-TGACGCACCACTGGTAGT-3’; and GAPDH RP, 5’-GATGCAGGATGATGTTTC-3’ [33]. Confluent mouse hepatoma cells (hepa1cl/c7) were treated with 1% carrier solvent (DMSO), 1 nM TCDD, or 10 μM ginsenoside for 4 h, respectively, prior to mRNA isolation using TRIzol (Invitrogen). Single stranded cDNA was synthesized using RevertAid First Strand cDNA Synthesis Kit (Fermentas) according to the manufacturer’s instructions and used for PCR amplification. PCR reactions were conducted in final volume of 20 μL, and performed on equal amounts of reverse-transcribed products, using SYBR Green Master mix and Rox reference dye, according to the manufacturer’s instructions (Promega). All PCR reactions were performed and analyzed in a Stratagene real-time PCR machine (MX3005P, USA). The specificity of amplification was confirmed by melting curves and by gel electrophoresis.

Preparation of Cytosol Extracts

Male Hartley guinea pigs (250–300 g), obtained from Charles River Breeding Laboratories (Wilmington, DE), were exposed to 12 h of light and 12 h of dark daily and were allowed free access to food and water. Hepatic cytosol was prepared in HEDG buffer (25 mM Heps [pH 7.5], 1 mM EDTA, 1 mM DTT, and 10% (v/v) glycerol) as previously described [21]. The resulting cytosolic extract was stored frozen at −80°C until use. Protein concentrations were determined by dye binding using bovine serum albumin as the standard. All procedures and experiments with animals and animal-derived materials were reviewed and approved by the University of California Davis Institutional Animal Care and Use Committee (approval ID 08-13392).

Gel Retardation Assay

Complementary synthetic oligonucleotides containing the DRE3 AHR DNA binding site 5’-GATCTGGCTCTTTCT-CACGGCAAATCCCGGAGG-3’ and 5’-GATCCGGAGTTGCGGGAA-GAA GAGCCA-3’ were prepared, annealed, and end-labeled with [3H]ATP as described [21]. Guinea pig hepatic cytosol (8 mg/ml in HEDG) was incubated for 2 h in a room temperature water bath with DMSO (2%), TCDD (20 nM), or the indicated ginsenoside (200 μM). An aliquot of the reaction was mixed with poly[dI·dC] and [3H]-DRE (100,000 cpm), and AHR-[3H]-DRE complexes were resolved by gel retardation analysis, visualized by autoradiography and quantified by phosphorimager analysis (Molecular Dynamics, Sunnyvale, CA USA) of the dried gels [21].

Ligand Binding Analysis

Aliquots of guinea pig hepatic cytosol (2 mg protein/ml) were incubated with 2 nM [3H]TCDD in the presence of DMSO (1%), TCDD (200 nM), the indicated solvent or ginsenoside (200 μM) for 2 h in a room temperature water bath. [3H]TCDD binding in aliquots of the incubation (200 μl) was determined by HAP binding as previously described [21]. The total amount of [3H]TCDD specific binding was obtained by subtracting the nonspecific binding ([3H]TCDD + TCDF) from the total binding ([3H]TCDD), and the ability of ginsenosides to bind to the AHR was indicated by their ability to competitively reduce [3H]TCDD specific binding.

Results

Agonist And Antagonist Activity of Ginsenosides in Guinea Pig G16l1.1c8 Cells

We first examined the AHR agonist activity of a series of ginsenosides by testing their ability to stimulate AHR-dependent reporter gene expression in recombinant guinea pig intestinal adenocarcinoma cells (G16l1.1c8) that contain the stably transfected DRE-luciferase reporter plasmid pGudLuc1.1. Concentration-dependent induction of luciferase by ginsenosides at 4 h was observed in this cell line, and some ginsenosides were found to stimulate AHR-dependent reporter gene expression at concentrations of 1 μM (Rh2, PPT) and 10 μM (Rb3, Re, Rh1, Rh2, F11, TG) (Figure 2). Both PPD and PPT reduced TCDD-dependent luciferase induction in the same cell line, and luciferase gene expression induced by TCDD was reduced by Rh2, PPD, PPT and F11 in guinea pig cell line.
Stimulation of AHR transformation and DNA binding by TCDD and ginsenosides in vitro

The reporter gene expression results demonstrated the ability of selected ginsengosides to activate AHR-dependent gene expression, but they did not address whether this induction was direct (i.e., the ginsenoside binds to and activates the AHR) or indirect (a metabolite of the ginsenoside binds to the AHR and/or it activates the AHR by a mechanism that does not involve direct binding to the AHR). To address this, we examined the ability of ginsenosides to directly stimulate transformation and DNA binding of guinea pig cytosolic AHR in vitro using gel retardation analysis. The results of these analyses (Figure 3) revealed that the ginsenosides Rc, Rh1, F11 and TG could stimulate AHR:DRE complex formation to a level greater than 40% of that maximally induced by TCDD, with Rc producing maximal AHR:DRE complex formation (99±6% of that of TCDD). While the DNA binding analysis results indicated that at least four ginsenosides could stimulate AHR transformation and DNA binding in vitro, we did not examine whether these compounds were actually AHR ligands.

Competitive Binding of Ginsenosides to The Guinea Pig Hepatic Cytosolic Ahr

To determine whether these ginsenosides were ligands for the AHR, we evaluated their ability to compete with [3H]TCDD for binding to the AHR. The results of these studies revealed that many ginsenosides (Table 2), including Rc, Rd, Re, Rg2, Rh1, Rh2, PPD, PPT, F11 and TG, could competitively bind to the AHR, displacing between 20 and 80% of [3H]TCDD specific
binding. Similar to its relatively high efficacy to stimulate AHR DNA binding, Re competitively displaced ~90% of [3H]TCDD specific binding. While competitive binding by Re, Rh1, Rh2, F11 and TG were consistent with their agonist activities in the gene expression studies, comparison of binding and gene expression data (Figure 2) suggested that these compounds were partial agonists. Interestingly, Re appeared to be a unique nonproductive AHR ligand for guinea pig in that it could effectively compete for ligand binding but not significantly stimulate or inhibit AHR-dependent gene expression, but it could induce AHR-dependent luciferase expression in rat cells (Table 3).

**Endogenous Gene Cyp1a1 Expression**

To confirm the ability of ginsenosides to induce expression of an endogenous AhR-responsive gene, we examined its effect on CYP1A1 expression (i.e., mRNA levels) using RT-PCR. Incubation of liver (hepa1c1c7) cells with ginsenosides (Re, Rh1, PPD, F11) for 4 h increased CYP1A1 mRNA levels, albeit to a lower level than that induced by TCDD (Figure 4), but these data were consistent with the reporter gene induction results and the AHR agonist activity of these ginsenosides.

**Molecular Docking on Homology Models**

To analyze the molecular determinants of the observed ability of several ginsenosides to compete with [3H]TCDD for binding to the gpAHR, PPD and PPT binding were computationally simulated. To this end, a homology model of the gpAHR LBD was developed using the procedure we previously described for other AHR LBDs [22], and ensemble docking calculations were performed for these ligands and TCDD (see Methods section for the details). The use of a homology model in lieu of an available experimental structure, along with the limitations of current docking methods in including protein flexibility during docking [34], prevented the use of the above computational protocol for modeling the binding of ginsenosides with larger molecular structures than PPD/PPT to the AhR.

Docking calculations predicted a binding pose for the TCDD in the middle of the gpAHR binding cavity (see Figure 5A). Since this cavity shares similar structural characteristics and conserved internal residues with other mammalian ARs with high TCDD affinity [35], the binding geometry was very similar to those predicted for mAhR and rAhR [22]. Moreover, the TCDD:gpAHR complex was stabilized by the same interactions previously predicted and validated by mutagenesis experiments of the TCDD:mAhR complex [36,37,22].

Stable docking poses were obtained also for PPD and PPT within the binding cavity, with very similar placements (see Figure 5A). The interactions that mainly stabilized binding of these ginsenosides (Figure 5B) involved the central polar residues (H290 and Q382), which interacted with the central hydroxyl groups of the ligands, as well as several hydrophobic residues at the entrance of the cavity (F294, M339 and M347) and lining the inner part of the cavity (F286, L307, L314 and L352). Some of these interactions were the same as those observed for TCDD. However, one difference was that TCDD is a relatively small molecule (228 Å³ volume), compared to PPD and PPT (389 Å³ and 390 Å³ volume, respectively) and in contrast to TCDD, the larger PPD and PPT molecules completely occupied the free internal space available in the LBD.

A confirmation of this precise fit between the ligand structures and the binding cavity features was supported by the results obtained by docking PPD and PPT to the mAHR, rtAhR and huAhR LBD models (data not shown). While docking poses similar to that described for gpAhR were obtained in the mAHR and rtAhR models, which share the same cavity features, no docking poses were obtained in the huAhR. There was a unique residue within the binding cavity of the huAhR (val381) that is different from that in the analogous position of the C57BL/6 mouse AhR LBD (ala375), and the lower affinity of TCDD for

---

**Table 2. Competitive binding of ginsenosides to the guinea pig hepatic cytosolic AHR.**

| Competitor | Concentration (µM) | [3H]-TCDD Specific Binding (Percent of Displacement)* |
|------------|--------------------|------------------------------------------------------|
| Rg1        | 200                | 6.1 ± 7.6                                            |
| Rb1        | 200                | 14.7 ± 7.4                                           |
| Rg2        | 200                | 21.2 ± 8.3b                                          |
| Rd         | 200                | 22.3 ± 6.2b                                          |
| Rh2        | 200                | 23.5 ± 17.4                                          |
| Rb3        | 200                | 23.7 ± 14.7                                          |
| F11        | 200                | 28.0 ± 9.1b                                          |
| TG         | 200                | 31.0 ± 1.5b                                          |
| Re         | 200                | 38.6 ± 12.0b                                         |
| PPD        | 200                | 45.5 ± 3.7b                                          |
| Rh1        | 200                | 45.9 ± 23.2b                                         |
| PPT        | 200                | 48.1 ± 3.5b                                          |
| Rh2        | 200                | 50.9 ± 4.4b                                          |
| Rc         | 200                | 88.2 ± 3.9b                                          |

Guinea pig hepatic cytosol was incubated with 2 nM [3H]-TCDD in the absence or presence of 200 nM TCDF or the indicated ginsenoside for 2 hours at 20 °C and [3H]-TCDD specific binding was determined using the hydroxyapatite binding assay as described in the Materials and Methods section. a Values were expressed as a percent of the total [3H]-TCDD specific binding and represented the mean ± SD of triplicate determinations. b Values represented that the amount of [3H]-TCDD specific binding was significantly displaced by the competitors at p < 0.05 (*) as determined by Student’s t-test.

doi:10.1371/journal.pone.0066258.t002
Table 3. Ginsenoside agonist activity in AHR-responsive recombinant guinea pig (G16L1.1c8), rat (H4L1.1c4), mouse (H1L1.1c2) and human (HG2L6.1c3) cells.

| Treatment | Chemical | Concentration | G16L1.1c8 | H4L1.1c4 | H1L1.1c2 | HG2L6.1c3 |
|-----------|----------|---------------|-----------|---------|---------|---------|
| TCDD      | 1 nM     | 100±0.12      | 100±0.11  | 100±0.16| 100±0.3 |
| Rb1       | 10 μM    | 1±0.2         | −1±0.2    | −1±0.1  | 3±2     |
| Rb2       | 10 μM    | 1±0.1         | −2±0.1    | −2±0.0  | 19±4b   |
| Rb3       | 10 μM    | 7±2b          | 13±3b     | 5±1     | 5±2     |
| Rc        | 10 μM    | 24±6b         | 23±6b     | 17±3b   | 19±2b   |
| Rd        | 10 μM    | 2±4           | 0±0       | −2±1    | 5±1     |
| Re        | 10 μM    | 0±3           | 38±13b    | 4±2     | 1±1     |
| Rg1       | 10 μM    | 0±2           | 12±0b     | 10±3b   | 1±1     |
| Rg2       | 10 μM    | 0±1           | 2±1       | 5±2     | 2±0     |
| Rh1       | 10 μM    | 27±2b         | 5±4       | 2±2     | 6±0     |
| Rh2       | 10 μM    | 29±4b         | 0±1       | 3±4     | 8±2b    |
| PPD       | 10 μM    | 0±2           | −3±1      | 4±2     | 5±2     |
| PPT       | 10 μM    | 4±2           | 6±3       | 7±1b    | 6±1     |
| F11       | 10 μM    | 12±3b         | 8±2b      | 3±4     | 6±1     |
| TG        | 10 μM    | 28±3b         | 3±2       | 2±3     | 7±2b    |

Cells were incubated with 10 μM of indicated ginsenoside for 4 hours and luciferase activity was determined as described in Materials and Methods section. * Values were expressed as the percentage of 1 nM TCDD induction and represented the mean ± SD of triplicate determinations. † Values were significantly different from the DMSO-treated sample at *p<0.05 as determined by Student’s t-test.

doi:10.1371/journal.pone.0066258.t003

Figure 4. Endogenous gene CYP1A1 expression in mouse hepatoma cells. Hepa1c1c7 cells were incubated with DMSO (1%), final concentration), TCDD (1 nM), or ginsenosides (10 μM) for 4 h at 37 °C, mRNA was extracted, subjected to RT-PCR and amplification. The asterisk indicated that the gene expression was significantly induced compared to DMSO-treated sample at *p<0.05 (*).

doi:10.1371/journal.pone.0066258.g004

Ginsenosides Are Novel AHR Ligands

huAHR was attributed to the steric hindrance imparted by this residue that reduces the cavity space available, and affects TCDD placement and interactions [22,33]. From our calculations, the presence of this residue in the modeled huAHR LBD, along with slight conformational differences of some hydrophobic residues in the inner part of the cavity, were sufficient to prevent PPD and PPT binding, although whether they actually interact with the huAHR remains to be determined. Finally, the ability of PPD and PPT to completely fill the available space in the gpAHR cavity (as well as in the mAHR and nAHR cavities) could result in a severe reduction in the flexibility of the domain and a consequential inhibition of the conformational changes associated with ligand activation of AHR. This observation would be more consistent with the activity of PPD and PPT as TCDD antagonists than AHR agonists, which awaits experimental confirmation.

Species Specificity Of Ginsenosides As Ahr Agonists In Rat, Mouse and Human Cell Lines

Dramatic species differences in the ability of chemicals to bind to and activate/inhibit the AHR have been previously reported [21,38]. The above results indicate the ability of various ginsenosides to bind to and activate the gpAHR. Docking analysis indicate the ability of at least PPT and PPT to interact with the receptors from various species (although docking results with the huAHR could not be determined). Accordingly, to examine the species specificity of ginsenosides as AHR agonists, we evaluated their ability to induce DRE-luciferase gene expression in stably transfected rat (H4L1.1c4), mouse (H1L1.1c2) and human (HG2L6.1c3) hepatoma cell lines. Similar to the results obtained with guinea pig cells, most ginsenosides were inactive as AHR agonists, Re is the only ginsenoside that consistently induced gene expression in guinea pig cells, rat and mouse cell lines (Figure 3 & Table 3). Rb3, Re, Rh2, Rh2, F11 and TG induced gene expression in guinea pig cells; Rh2, Re and Rh2 induced gene expression in human cells.
Dose-Dependent Induction Luciferase Activity of Rc In Different Cell Lines

Considering that Rc was the most efficacious ligand in the DNA and ligand binding assays, we chose Rc to examine the ability of different concentrations to induce luciferase reporter gene activity in cell lines from different species. Dose-dependent induction of luciferase by Rc at 4 h was observed to levels greater than 75% of that induced by 1 nM TCDD in guinea pig, rat, mouse and human cell lines (Figure 6). The EC_{50} values of luciferase induction by Rc in G16L1.1c8, H4L1.1c4, H1L1.1c2 and HG2L6.1c3 cells were 11.5 μM, 100 μM, 127 μM and 13.3 μM, respectively. These results indicated that Rc was a relatively weak AHR agonist when compared to TCDD and other potent HAH and PAH ligands in these cell lines. Taken together, our results demonstrate the ability of selected ginsenosides to stimulate and/or inhibit the functionality of the AHR and AHR-dependent gene expression, with some compounds exhibiting species- and/or cell-specific differences in AHR responsiveness. Thus, ginsenosides represent a new class of naturally-occurring AHR ligands with compound selective agonist, antagonist or nonproductive ligand effects.

Discussion

The AHR is a transcription factor that responds to structurally diverse ligands, and the activation of the AHR signal transduction pathway not only produces a spectrum of ligand-, species- and tissue-specific toxic and biological responses, but also plays a critical role in immune function, cardiovascular physiology and other endogenous functions [1–3]. Although TCDD and related toxic environmental contaminants have been extensively characterized as AHR ligands, an increasing number of reports have demonstrated the ability of a variety of endogenous chemicals and naturally occurring dietary compounds to interact with and activate the AHR and AHR signaling pathway. For example, numerous dietary phytochemicals have been shown to bind and/or modulate AHR action, and these include diindolylmethane, indole-3-carbinol (I3C) and its acidic condensation product indolo-[3,2b]carbazole, and various flavonoids, carotenoids and other chemicals [39–42]. In fact, recent studies have reported the ability of dietary AHR active compounds present in cruciferous vegetables to promote intestinal immune function, revealing the AHR as a critical link between diet and immunity [43,44].

Here, we have demonstrated for the first time the ability of several naturally-occurring ginsenosides to directly bind to and activate/inhibit the AHR and AHR signal transduction pathway. Interestingly, our results indicate a divergence in response for these compounds, with several ginsenosides (e.g. Rc and Rh1) exhibiting pure AHR agonist activity, albeit as relatively weak agonists, while other compounds (e.g. Rh2, PPD and PPT) exhibited AHR antagonist activity, in that they could directly bind to the AHR, yet inhibited TCDD-dependent induction of AHR-responsive luciferase gene expression. In contrast, other ginsenosides like F11, the unique component found in American but not Asian ginseng species, exhibited novel AHR activity in that it could exert both agonist and antagonist activity at the same concentration. F11 could competitively bind to the AHR, stimulate AHR transformation, and DNA binding (agonist activity), but it also could inhibit TCDD induced AHR-dependent luciferase reporter gene expression (antagonist activity). While the mechanism of this novel action remains to be determined, this differential response could contribute to some of the differences in the biological and physiologic effects produced by American versus Asian ginseng species.

Comparison of the ability of each ginsenoside to induce AHR-dependent luciferase gene expression in cell lines from different species has revealed some interesting similarities and differences in species-specificity in response to these compounds. The ability of Rc to induce AHR-dependent gene expression to a comparable level in guinea pig, mouse, rat and human cell lines indicated that Rc was an AHR agonist of comparable potency/efficacy in each of these species. In contrast, comparison of luciferase gene induction in guinea pig, mouse, rat and human cells by all ginsenosides revealed numerous other ginsenosides exhibited species-/cell-
specific differences in AHR agonist activity (Table 3). For example, ginsenoside Re induced luciferase to 38% of that of TCDD in rat H4L1.1c4 cells, yet little or no induction was observed in mouse, guinea pig or human cells. Similarly, Rh1 and TG induced luciferase activity in guinea pig cells to between 25–30% of that induced by TCDD, yet little or no induction was observed in other cells, while Rb2 could induce luciferase activity only in human cells to 19%. Rc induced luciferase activity in all the cell lines we used. While differences in cellular metabolism between these cell lines (i.e. differences in metabolic degradation of these compounds in different cell lines) could contribute to these species differences, species-specific differences in key amino acids within the ligand binding pocket of the AHR could also contribute to this differential response. In fact, comparison of the AHR ligand binding domain from different species revealed significant differences in amino acids within the ligand binding pocket [35,37], and species-specific differences in AHR ligand binding specificity have previously been reported by several laboratories [10,11]. While molecular docking approaches provided one avenue to examine specific interactions of ligands with amino acids within the modeled ligand binding pocket of the AHR from several species, current limitations as described above precluded our specific binding analysis of the majority of the ginsenosides. However, docking results with PPT and PPD not only revealed similarities in the specific binding interactions of these compounds within the gpAHR LBD, but also similarities in ligand binding characteristics between species. Whether species-specific binding interactions actually occur remains to be experimentally verified. In addition to ligand binding, the reported ability of various ginsenosides to affect cell signaling pathways and enzymes, coupled with the documented ability of some cell signaling pathways to affect AHR-dependent gene expression suggest that species- and/or cell-specific differences in these or other targets could contribute to the observed differences in AHR ligand efficacy and response [3,45], although this remains to be confirmed. Taken together, these results confirmed AHR agonist activity of several ginsenosides in several species.

Comparing the relative activity of the ginsenosides in different AHR-based assays, some discrepancies in activity were apparent. For example, differences in the relatively efficacy/activity of Rc were observed in the guinea pig AHR bioassays. While Rc could stimulate AHR transformation and DNA binding to a level comparable to that of a maximal activating concentration of TCDD (Figure 3), AHR-dependent reporter gene activity was stimulated to only ~24% of that of TCDD in the guinea pig cell line (Figure 2). Similar differences in AHR ligand efficacy/potency

**Figure 6.** Dose-dependent induction of luciferase activity by TCDD and Rc in AHR-responsive recombinant guinea pig (G16L1.1c8), rat (H4L1.1c4), mouse (H1L1.1c2) and human (HG2L6.1c3) cells. Cells were incubated with the indicated concentration of Rc for 4 h and luciferase activity was determined as described in Materials and Methods section. Dose-dependent induction of luciferase activity by TCDD and Rc in (A) G16L1.1c8, (B) H4L1.1c4, (C) H1L1.1c2 and (D) HG2L6.1c3 cells were shown. Values were expressed in the figure as the percentage of maximal TCDD induction and represented the mean ± SD of triplicate determinations. All concentrations of TCDD ≥10⁻¹¹ M and of Rc ≥10⁻³ M were significantly greater than DMSO-treated sample at p<0.01 as determined by Student’s t-test. doi:10.1371/journal.pone.0066258.g006
between in vitro and cell-based AHR assays have been previously observed and primarily resulted from the greater efficiency of a ligand to activate the cytosolic AHR in vitro, since the ligand has direct access to the AHR with little degrading enzymes present [46,47]. A comparable response in intact cells would require all of the added ligand to enter the cell (without loss to serum proteins), it must avoid sequestration (by membranes, lipids, proteins, and organelles) and metabolism (by enzymes such as cytochrome P450s), and must find and bind to the AHR, fully stimulating AHR nuclear localization, transformation and DNA binding, and induction of gene expression, all within the time frame of the bioassays. Considering that ginsenosides appear to be highly susceptible to metabolism, significant reductions in their inducing potency in cell based assays are expected.

Major biological effects of ginsenosides include the enhancement of cholesterol biosynthesis [48], immunomodulatory and anti-inflammatory activity [49], anti-diabetic and antioxidant effects [50,51], cardiovascular protection [52], chemotherapeutic activities and neuroprotective effects [52,53]. To date, more than 30 ginsenosides have been found in extracts of P. ginseng, with more than 60 isolated from members of the Panax genus; these include the oleanolic acid type ginsenosides (including R0), the 20(S)-protopanaxatriol (PPT) type ginsenosides (including Rb1, Rb2, Rc, Rd, Re, Rg1, Rg2, Rg3, Rh2 and Rs) and the 20(S)-protopanaxadiol (PPD) type ginsenosides (including Re, Rf, Rg1, Rg2 and Rh1). While many of these compounds have shown to contribute to the wide range of medicinal effects of ginseng, it is likely that many distinct mechanisms of action (biological and toxic) exist for these different compounds, of which activation/inhibition of the AHR signaling pathway is only one. Considering the currently large consumption of ginseng and the diversity in effects, it is suggested that more extensive studies should be conducted on the biological and physiologic effects and mechanism of ginsenosides. Whether ginsenosides exert some of their beneficial clinical effects through an AHR-dependent pathway, and how exactly these structurally unique chemicals can bind within the AHR ligand binding pocket and activate/inhibit the AHR are exciting areas for future research.

References

1. Schmidt JV, Bradfield CA (1996) Ah receptor signaling pathways. Annu Rev Cell Dev Biol 12: 55–89.
2. Safe S (1990) Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs), dibenzofurans (PCDFs), and related compounds: environmental and mechanistic considerations which support the development of toxic equivalence factors (TEFs). Crit Rev Toxicol 21: 51–88.
3. Denison MS, Soshilov AA, He G, DeGroot DE, Zhao B (2011) Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. Toxicol Sci 124: 1–22.
4. Kazzazka A, Poelinger L, Pongratz I (1999) Evidence that the co-chaperone p23 regulates ligand responsiveness of the dioxin (Aryl hydrocarbon) receptor. J Biol Chem 274: 13519–13524.
5. Meyer BK, Pray-Grant MG, Vandene Heuvel JP, Perdew GH (1998) Hepatitis B virus X-associated protein 2 is a subunit of the unliganded aryl hydrocarbon receptor core complex and exhibits transcriptional enhancer activity. Mol Cell Biol 18: 978–981.
6. Hankinson O (1995) The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 35: 307–340.
7. Soshilov A, Denison MS (2011) Ligand displaces heat shock protein 90 from overlapping binding sites within the aryl hydrocarbon receptor ligand-binding domain. J Biol Chem 286: 33275–33282.
8. Denison MS, Seidel SD, Rogers VJ, Zacirnai M, Winter GM, et al. (1998) Natural and synthetic ligands for the Ah receptor. Molecular Biology Approaches to Toxicology (Puga A, Kendall RJ, eds). London: Taylor and Francis, 3–33.
9. Ashida H, Fukuda I, Yamashita T, Kanazawa K (2000) Flavones and flavonols at dietary levels inhibit a transformation of aryl hydrocarbon receptor induced by dioxin. FEBS Lett 476: 213–217.
10. DeGroot D, He G, Fraccalvieri D, Bonati L, Pandini A, et al. (2011) AHR ligands: promiscuity in binding and diversity in response. In: The Ah receptor in cancer cells in nude mice. Oncol. J Cancer Res Clin.120: 24–36.
11. Denison MS, Nagy SR, Denison NS (2004) Comparison of recombinant cell biosassays for the detection of Ah receptor agonists. Biofactors 20(1): 11–22.
12. Denison MS, Rogers JM, Rushing SR, Jones CL, Tetangco SC, et al. (2002) Analysis of the Ah receptor signal transduction pathway. in: Current Protocols in Toxicology (Maines M, Costa LG, Reed DJ, Sassa S and Sipes IG, eds.). pp 4.8.1–4.8.45. John Wiley and Sons, NY.
13. Motto I, Bordogna A, Soshilov AA, Denison MS, Bonati L (2011) New Aryl Hydrocarbon Receptor Homology Model Targeted to Improve Docking Reliability. J Chem Inf Model 51: 2800–2811.
14. Sali A, Bhandell TL (1995) Comparative protein modeling by satisfaction of spatial restraints. J Mol Biol 254: 773–815.
15. Marti-Renom MA, Stuart A, Fiser A, Sanchez R, Melo F, et al. (2000) Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 29: 291–325.
16. Fiser A, Do RK, Sali A (2000) Modelling of loops in protein structures. Protein Sci 9: 1753–1773.
17. Shem M, Sali A (2006) Statistical potential for assessment and prediction of protein structures. Protein Sci 15: 2507–2524.
18. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, et al. (2006) Glide, version 5.8, Schrödinger, LLC: New York, NY.
19. MacroModel, version 9.9, Schrödinger, LLC: New York, NY, 2012.
20. Maestro, version 9.3, Schrödinger, LLC. New York, NY, 2012.
21. Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL (2001) Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides. J Phys Chem B 105: 6474–6487.
22. Still WC, Temprany A, Haveldy RC, Hendrickson TA (1990) General treatment of solvation for molecular mechanics. J Am Chem Soc 112: 6127–6129.
23. Glide, version 5.8, Schrödinger, LLC. New York, NY, 2012.
24. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, et al. (2006) Extra precision Glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49: 6177–6196.
25. Shigeyuki Uno, Karii Endo, Yuji Ishida, Chise Tateno, Makoto Makishima, et al. (2009) CYP1A1 and CYP1A2 expression: Comparing ‘humanized’ mouse lines and wild-type mice; comparing human and mouse Paxtona-derived cell lines. Toxicology and Applied Pharmacology 237: 119–126.
26. Bordogna A, Pandini A, Bonati L (2011) Predicting the accuracy of protein–ligand docking on homology models. J Comput Chem 32: 81–98.

Acknowledgments

We thank Dr. Steven Safe for the TCDD and [3H] TCDD. We are also thank Angela C. Zhang for her technical writing help and comments during the manuscript preparation.

Author Contributions

Conceived and designed the experiments: QH GH JZ AS MSD LB BZ. Performed the experiments: QH GH JZ AS DF. Analyzed the data: QH GH JZ AS MSD LB BZ. Contributed reagents/materials/analysis tools: AZ HY. Wrote the paper: QH GH JZ AS MSD LB BZ.
35. Fraccalvieri D, Soshilov AA, Karchner SI, Franka DG, Pandini A, et al. (2013) Comparative analysis of homology models of the Ah receptor ligand binding domain: verification of structure-function predictions by site-directed mutagenesis of a non-functional receptor. Biochemistry 52:714–725.

36. Pandini A, Denison MS, Song Y, Soshilov AA, Bonati L (2007) Structural and functional characterization of the Ah receptor ligand binding domain by homology modeling and mutational analysis. Biochemistry 46: 696–706.

37. Pandini A, Soshilov AA, Song Y, Zhao J, Bonati L, et al. (2009) Detection of the TCDD binding fingerprint within the Ah receptor ligand binding domain by structurally driven mutagenesis and functional analysis, Biochemistry 48: 5972–5983.

38. Denison MS, Vella LM, Okey AB (1986) Structure and function of the Ah receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin. Species difference in molecular properties of the receptors from mouse and rat hepatic cytosols. J Biol Chem 261: 5905-5925.

39. Bjeldanes LF, Kim JV, Grose KR, Bartholomew JC, Bradfield CA (1991) Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc Natl Acad Sci U S A 88: 9543–9547.

40. Ciolino HP, Daschner PJ, Yeh GC (1998) Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res 58: 5097–5102.

41. Henry EC, Gasiewicz TA (2003) Agonist but not antagonist ligands induce conformational change in the mouse aryl hydrocarbon receptor as detected by partial proteolysis. Mol Pharmacol 63: 390–400.

42. Mukai R, Shirai Y, Saito N, Fukuda I, Nishiumi S, et al. (2010) Suppression mechanisms of flavonoids on aryl hydrocarbon receptor-mediated signal transduction. Arch Biochem Biophys 501: 134–141.

43. Hooper LV (2011) You AHR what you eat: linking diet and immunity. Cell 147: 489–491.

44. Li Y, Innocentini S, Withers DR, Roberts NA, Gallagher AR, et al. (2011) Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell 147: 620–629.

45. Puga A, Ma C, Marlowe JI (2009) The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem Pharmacol 77: 713–722.

46. Nagy SR, Sanden JR, Harnack BD, Denison MS (2002) Development of a green fluorescent protein-based cell bioassay for the rapid and inexpensive detection and characterization of ah receptor agonists. Toxicon 35: 200–210.

47. Seidel SD, Li V, Winter GM, Rogers VJ, Martinez EL, et al. (2006) Ah receptor-based chemical screening bioassays: application and limitations for the detection of Ah receptor agonists. Toxicon 35: 107–113.

48. Sakakibara K, Shibata Y, Higashi T, Sanada S, Shoji J (1975) Effect of ginseng saponins on cholesterol metabolism. I. The level and the synthesis of serum and liver cholesterol in rats treated with ginsenosides. Chem Pharm Bull (Tokyo) 23: 1009–1016.

49. Joh EH, Lee JA, Jung IH, Kim DH (2011) Ginsenoside Rh1 and its metabolite compound K inhibit IRAK-1 activation-the key step of inflammation. Biochemical pharmacology 82: 276–286.

50. Aistle AS, Zhou YP, Xie JT, Wu JA, Zhang L, et al. (2002) Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes 51: 1851–1858.

51. Lee KT, Jung TW, Lee HJ, Kim SG, Shin YS, et al. (2011) The antidiabetic effect of ginsenoside Rb1 via activation of AMPK. Archives of pharmacal research 34: 1201–1208.

52. Chen X (1996) Cardiovascular protection by ginsenosides and their nitric oxide releasing action. Clinical and experimental pharmacology and physiology 23: 720–732.

53. Sato K, Mochizuki M, Saki I, Yoo YC, Hamukawa K, et al. (1994) Inhibition of tumor angiogenesis and metastasis by a saponin of Panax ginseng, ginsenoside-Rb1. Biological & pharmaceutical bulletin 17: 635–639.